BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hydroxyurea (Siklos) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Hydroxyurea (Siklos)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06578507-10310@assetmemo.bio
DTSTAMP:20261121T005410Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Hydroxyurea (Siklos): Phase 2 readout est. (NCT06578507)
DESCRIPTION:Hydroxyurea (Siklos)\, phase 2\, Sickle Cell Disease.\nStudy: P
 harmacokinetics\, Efficacy and Safety of Twice Daily Dosing Regimen of Hyd
 roxycarbamide Dispersible Tablets in Children With Sickle Cell Disease\nEs
 timated primary completion: February 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/hydroxyurea-siklos#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06578507
URL:https://assetmemo.bio/drug/hydroxyurea-siklos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708714-10310@assetmemo.bio
DTSTAMP:20261121T005410Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Hydroxyurea (Siklos): Phase 1/2 readout est. (NCT07708714)
DESCRIPTION:Hydroxyurea (Siklos)\, phase 1/2\, Sickle Cell Disease.\nStudy:
  Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Mal
 aria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study\nEstimat
 ed primary completion: 30 November 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/hydroxyurea-siklos#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07708714
URL:https://assetmemo.bio/drug/hydroxyurea-siklos#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
